Liminatus Pharma, Inc. Gains 87.36%
Tue, Feb 03, 2026 at 07:54 PM
Liminatus Pharma, Inc. (LIMN:NASDAQ) soared at $1.07, representing a gain of 87.4%. On Tue, Feb 03, 2026, LIMN:NASDAQ touched a New 2-Week High of $1.07. From Wed, Jan 21, 2026, the stock recorded 33.33% Up Days and 30.00% Green Days
About Liminatus Pharma, Inc. (LIMN:NASDAQ)
Liminatus Pharma, Inc. is pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies.
Top 10 Gainers:
- Movella Holdings Inc. (MVLA:NASDAQ), 425%
- F45 Training Holdings Inc. (FXLV:NYSE), 350%
- Tian Ruixiang Holdings Ltd (TIRX:NASDAQ), 98.41%
- Liminatus Pharma, Inc. (LIMN:NASDAQ), 87.36%
- UTime Limited (WTO:NASDAQ), 83.18%
- Gaxos.ai Inc. (GXAI:NASDAQ), 41.84%
- FatPipe, Inc. (FATN:NASDAQ), 41.3%
- JBDI Holdings Limited (JBDI:NASDAQ), 33.33%
- Phaos Technology Holdings (Cayman) Limited Class A (POAS:NYSEMKT), 33.07%
- P3 Health Partners Inc. (PIII:NASDAQ), 32.89%